249 studies found for:    209as209
Show Display Options
Rank Status Study
1 Terminated Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
Condition: Autism Spectrum Disorders
Intervention: Drug: STX209 (arbaclofen)
2 Completed Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia
Condition: Hypercholesterolemia
Interventions: Drug: LGT209;   Drug: Placebo
3 Completed Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins
Conditions: Hypercholesterolemia,;   LDL Cholesterol
Interventions: Drug: LGT209 50 mg;   Drug: LGT209 300 mg;   Drug: Placebo;   Drug: Statins (atorvastatin or simvastatin)
4 Recruiting Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC)
Condition: Viral Conjunctivitis
Interventions: Drug: APD-209 Eye drops;   Drug: APD-209 Placebo Eye drops
5 Completed Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
Condition: Fragile X Syndrome
Interventions: Drug: arbaclofen;   Drug: Placebo
6 Completed
Has Results
Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome
Condition: Fragile X Syndrome
Interventions: Drug: STX209;   Drug: Placebo
7 Terminated An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders
Condition: Autism Spectrum Disorders
Intervention: Drug: arbaclofen
8 Completed Pilot Study of APD209 in Cancer Cachexia
Condition: Cancer-related Cachexia
Intervention: Drug: APD209
9 Terminated An Open Label Extension Study of STX209 in Subjects With Fragile X Syndrome
Condition: Fragile X Syndrome
Intervention: Drug: Arbaclofen
10 Completed Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome
Condition: Fragile X Syndrome
Interventions: Drug: arbaclofen;   Drug: placebo
11 Completed
Has Results
Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders
Condition: Autism Spectrum Disorders
Intervention: Drug: Arbaclofen
12 Completed Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma
Conditions: Recurrent Melanoma;   Stage IA Melanoma;   Stage IB Melanoma;   Stage IIA Melanoma;   Stage IIB Melanoma;   Stage IIC Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma
Interventions: Biological: HPV 16 E7:12-20 peptide vaccine;   Biological: gp100:209-217(210M) peptide vaccine;   Other: laboratory biomarker analysis
13 Completed Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IA Melanoma;   Stage IB Melanoma;   Stage IIA Melanoma;   Stage IIB Melanoma;   Stage IIC Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Biological: gp100:209-217(210M) peptide vaccine;   Biological: HPV 16 E7:12-20 peptide vaccine;   Other: laboratory biomarker analysis
14 Terminated An Open Label Extension Study in Subjects With Fragile X Syndrome
Condition: Fragile X Syndrome
Intervention: Drug: arbaclofen
15 Completed Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma
Conditions: Recurrent Melanoma;   Stage IV Melanoma
Interventions: Biological: aldesleukin;   Biological: gp100:209-217(210M) peptide vaccine;   Other: laboratory biomarker analysis
16 Completed
Has Results
Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma
Condition: High-Risk Melanoma
Interventions: Drug: gp100:209-217 (210M);   Drug: Montanide ISA-51;   Drug: Imiquimod
17 Completed Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Condition: Autism Spectrum Disorders
Intervention: Drug: Arbaclofen
18 Completed Biomarker and DNA Collection in Subjects Participating in Protocol 22003
Condition: Fragile X Syndrome
Intervention: Drug: STX209
19 Completed Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001
Condition: Fragile X Syndrome
Intervention: Drug: STX209
20 Completed MS 209 Plus Docetaxel in Treating Patients With Advanced Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: docetaxel;   Drug: dofequidar fumarate

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years